Filters

CDK7 (45H1) Monoclonal Antibody

CDK7 (45H1) Monoclonal Antibody size: 0.1ml 362

Price 362
Size 0.1ml
Long nameCDK7 (45H1) Monoclonal Antibody
Also known asCDK7 (45H1) Monoclonal Antibody
CategoryPrimary Antibodies
ConjugationUnconjugated
Target AntigenCDK7
SpecificityThis is a highly specific antibody against CDK7
Modification(s)None
Modification site(s)Unmodified antibody
ClonalityMonoclonal
Clone number45H1
Concentration1ug per 1ul
Source), Recombinant human protein purified from E, a, coli(His/ABD-CDK7 136-346 a
Gene ID number1022
Swiss ProtP50613
Tested Applications IP, WB
Recommended dilutions0 ug), 2 ug/mL) IP (2, WB (0
Cross reactivityHuman
Cross reactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Background of the target antigen CAK activates the cyclin-associated kinases CDK1, CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), CDK1, CDK2, CDK2, CDK4, CDK4 and CDK6 by threonine phosphorylation, CDK6 and CDK11B/CDK11, CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex, Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle, Each different complex controls a specific transition between 2 subsequent phases in the cell cycle, Its expression and activity are constant throughout the cell cycle, POLR2A, Phosphorylates SPT5/SUPT5H, Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA, Required for DNA-bound peptides-mediated transcription and cellular growth inhibition, Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, SF1/NR5A1, Upon DNA damage, allowing its escape from the promoter and elongation of the transcripts, and for activation of CDK2/cyclins during G1-S transition (but not complex formation), but is inactivated in turn by p53/TP53, helping in cell recovery, or to apoptosis, p53/TP53, this feedback loop may lead to an arrest of the cell cycle and of the transcription, thus regulating cell cycle progression, triggers p53/TP53 activation by phosphorylation, Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription
Purification methodPurified by Protein G
Storage conditions 50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA
Synonym names 39 kDa protein kinase, CAK1, CDK-activating kinase 1, CDK7, CDKN7, Cell division protein kinase 7, Cyclin-dependent kinase 7, HCAK, MO15, STK1, Serine/threonine-protein kinase 1, TFIIH basal transcription factor complex kinase subunit, p39 Mo15, p39MO15, CAK
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°
About Each murine monoclonal anibody has his own affinity specific for the clone, Mouse monoclonal antibodies are purified protein A or G and can be conjugated to FITC for flow cytometry or FACS and can be of different isotypes, Monoclonals of this antigen are available in different clones
Gene targetCDK7 (45H1) Monoclonal
Short nameCDK7 (45H1) Monoclonal Antibody
Technique Monoclonals or monoclonal antibodies, antibodies against human proteins, antibodies for, Antibody
Alternative nameCDK7 (45H1) monoclonal (Antibody to)
Alternative techniqueantibodies
Identity 1778
Gene CDK7
Long gene name cyclin dependent kinase 7
Synonyms gene name Xenopus laevis, cdk-activating kinase) , cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) cyclin-dependent kinase 7 (MO15 homolog
Synonyms CAK1 CDKN7 MO15 STK1 CAK
Locus 5q13, 2
Discovery year 1994-12-16
Entrez gene record 1022
Pubmed identfication 8069918
RefSeq identity NM_001799
Classification Cyclin dependent kinases
Havana BLAST/BLAT OTTHUMG00000099358

Subscribe to our Newsletter